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of different markers and context in which Tregs were ana-
lyzed. This resulted in a rationally composed ranking list 
of “Treg markers”. Subsequently, the proposed Treg mark-
ers were tested to get insight into the overlap/differences 
between the most frequently used Treg definitions and their 
utility for Treg detection in various human tissues. Here, 
we conclude that the CD3, CD4, CD25, CD127, and FoxP3 
markers are the minimally required markers to define 
human Treg cells. Staining for Ki67 and CD45RA showed 
to provide additional information on the activation status 
of Tregs. The use of markers was validated in a series of 
PBMC from healthy donors and cancer patients, as well as 
in tumor-draining lymph nodes and freshly isolated tumors. 
In conclusion, we propose an essential marker set compris-
ing antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, 
and CD45RA and a corresponding robust gating strat-
egy for the context-dependent analysis of Tregs by flow 
cytometry.
Abstract Regulatory T cell (Treg)-mediated immuno-
suppression is considered a major obstacle for successful 
cancer immunotherapy. The association between clinical 
outcome and Tregs is being studied extensively in clinical 
trials, but unfortunately, no consensus has been reached 
about (a) the markers and (b) the gating strategy required 
to define human Tregs in this context, making it difficult 
to draw final conclusions. Therefore, we have organized an 
international workshop on the detection and functional test-
ing of Tregs with leading experts in the field, and 40 par-
ticipants discussing different analyses and the importance 
This work has been presented previously on a poster at the CIMT 
annual meeting 2014 in Mainz, Germany, and at the SITC annual 
meeting 2014 in National Harbor, USA.
The collaborators of the CIMT immunoguiding program (CIP) 
regulatory T cell workshop are listed in “Appendix”.
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Abbreviations
ATP  Adenosine triphosphate
aTreg  Activated Treg
CIP  CIMT immunoguiding Program
CxCa  Cervical cancer
FMO  Fluorescence minus one
HD  Healthy donors
ICS  Intracellular cytokine staining
LN  Lymph node
MIATA  Minimal information about T cell assays
nTreg  Naïve Tregs
OS  Overall survival
OvCa  Ovarian cancer
SLE  Systemic lupus erythematosus
SOP  Standard operation procedures
TDLN  Tumor-draining lymph nodes
TIL  Tumor-infiltrating lymphocyte
Treg  Regulatory T cell
Introduction
Tregs play a key role in the regulation of self-tolerance 
and the maintenance of tissue homeostasis. Several 
human diseases such as autoimmune and immunode-
ficient conditions, chronic infections, and cancer have 
been associated with alterations in Treg numbers or 
function, and these alterations may contribute to dis-
ease progression and impact patient survival [1–3]. In 
cancer patients, it is well established that accumula-
tion of Tregs is associated with tumor progression, poor 
prognosis, and the suppression of anti-tumor immune 
effector functions. Treg-mediated immunosuppression 
is therefore considered a major obstacle for successful 
cancer immunotherapy [4–6]. Given their potential to 
affect the outcome of immunotherapy trials, Tregs are 
being studied extensively in this context. The multitude 
of Treg definitions in the reported studies and the lack of 
functional Treg testing in immunomonitoring of clinical 
trials, however, make correct interpretation of data and 
comparisons between studies difficult, especially since 
knowledge of overlap between the identified Treg popu-
lations is missing and the methods to detect these cells 
differ per laboratory. As a result, blurred pictures emerge 
with respect to associations between clinical outcome 
and Tregs [7]. So far, Tregs have been identified through 
a number of different (combinations of) markers includ-
ing CD4pos, Foxp3pos/hi, CD25pos/hi, CD127neg/low, CTLA-
4pos, CD45RApos/neg, Heliospos, CD39pos, and CD73pos/neg 
using several different gating strategies [8–15]. The lat-
ter may form an important addition to misinterpretation 
of data sets since differences in gating strategies were 
found to be the biggest source for interassay variation 
in flow cytometry-based intracellular cytokine staining 
(ICS) assays [16, 17]. Similarly, a lack of adequate con-
trols to guide the settings of gates may add another level 
of complexity to the analysis of Tregs.
To address these issues, the CIP organized a workshop 
on October 29, 2013 on the detection and functional testing 
of Tregs. This workshop, which hosted 40 researchers from 
seven countries in Europe and the USA, brought together 
leading experts in the field to (1) understand the state of 
the art of Treg research and to (2) define the most appropri-
ate assays/markers to measure, quantify, and functionally 
assess Tregs within patient samples. As it became appar-
ent during the workshop that a multitude of markers and 
combinations thereof is currently being used by the partici-
pants, a rationally composed ranking list of “Treg markers” 
was generated by the participants in the follow-up of the 
meeting. The preparation of this Treg marker list, subse-
quent data interpretation of the experiments performed at 
the LUMC, and subsequent discussions about and approval 
of the final conclusions were done through a series of cir-
culating emails. Subsequently, the proposed Treg markers 
were tested in order to get insight into the overlap/differ-
ences between the most frequently used Treg definitions 
and their utility for Treg detection in various human tissues. 
This led to a context-dependent [i.e., peripheral blood/
tumor/lymph node (LN)] essential marker set and robust 
gating strategy for the analysis of Tregs by flow cytometry.
Materials and methods
Cell samples
We acknowledge the concept of the minimal informa-
tion about T cell assays (MIATA) reporting framework 
11 Laboratory of Immunology, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, 
Bethesda, MD, USA
12 Duke Center for AIDS Research, Duke University, Durham, 
NC, USA
13 Department of Surgery, Duke University Medical Center, 
Durham, NC, USA
14 Centre for Molecular Medicine Norway, Nordic EMBL 
Partnership, University of Oslo and Oslo University Hospital, 
Oslo, Norway
15 K.G. Jebsen Centre for Cancer Immunotherapy 
and Biotechnology Centre, University of Oslo, Oslo, Norway
16 Department of Pathology, University of Pittsburgh Cancer 
Institute, Pittsburgh, PA, USA
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for human T cell assays [18]. Venous blood samples 
of healthy donors (HD) and recurrent ovarian cancer 
(OvCa) patients undergoing chemo-immunotherapeutic 
treatment (EM Dijkgraaf et al. submitted for publica-
tion) were drawn into sodium heparin collection tubes 
(Greiner Bio-one, Alphen a/d Rijn, the Netherlands) 
after signing informed consent. PBMCs were isolated 
using Ficoll (LUMC pharmacy, Leiden, the Nether-
lands) density gradient centrifugation, washed with 
PBS (B. Braun, Melsungen, Germany), cryopreserved 
in 90 % fetal calf serum (FCS; PAA Laboratories, Pas-
ching, Austria) and 10 % DMSO (Sigma-Aldrich, St. 
Louis, MO, USA), and stored in the vapor phase of liq-
uid nitrogen until further use [19]. TDLN and tumor 
samples were obtained from cervical cancer patients 
(CxCa) within the CIRCLE study after signed informed 
consent. The CIRCLE study investigates cellular immu-
nity against HPV in HPV-induced (pre)malignant lesions 
and was approved by the Medical Ethical Committee 
of the LUMC [20]. Single-cell suspensions were pre-
pared from TDLN and tumor samples using collagenase/
DNase digestion or gentle MACS procedure, respec-
tively. First, TDLN and tumor samples were cut into 
small pieces. Single-cell suspensions were prepared by 
incubating the TDLN pieces with 250 U/ml collagenase 
D (Roche, Almere, the Netherland) and 50 µg/ml DNase 
I (Roche) for 1 h at 37 °C, after which the TDLN was 
put through a cell strainer [21]. Single-cell suspen-
sions of tumor samples were prepared by incubating the 
tumor pieces for half an hour at 37 °C in IMDM/10 % 
human AB serum (Greiner) supplemented with 50 µg/
ml gentamycin (Life technologies, Bleiswijk, the Neth-
erlands), 25 µg/ml Fungizone (Life Technologies), 10 % 
penicillin/streptomycin (Sigma), 1 mg/ml collagenase 
D, and 50 µg/ml DNAse I (dissociation mix), followed 
by gentleMACS dissociation procedure according to the 
manufacturers’ instructions. Next, cells were frozen and 
stored as above. The handling and storage of the PBMC, 
TDLN, and tumor samples were done according to the 
standard operation procedures (SOP) of the department 
of Clinical Oncology at the LUMC by trained person-
nel. The use of the above-mentioned patient materials 
was approved by the Medical Ethics Committee Leiden 
in agreement with the Dutch law for medical research 
involving humans.
Treg enumeration by flow cytometry
The cryopreserved cell samples were thawed accord-
ing to SOPs and as described before [19], and Treg 
subsets were assessed by flow cytometry staining. To 
this end, one million PBMCs or ~250,000–750,000 
TDLN or tumor sample cells was used per condition. 
Since it has been described that Foxp3 staining can be 
highly variable and depend on the choice of antibody 
(clone), buffer, and/or fluorochrome [22–24] and the 
performance of a specific antibody is optimized by the 
manufacturer using their own permeabilization proce-
dures, optimal Foxp3 staining was determined first. We 
selected four different Foxp3 antibodies on the basis 
of in-house availability, compatibility with the rest of 
our panel and with the LSR Fortessa optical configura-
tion, and two different intranuclear staining kits. Opti-
mal staining was determined by the analysis of the 
percentage of positive cells and at the strength of the 
positive signal (compared to the negative fluorescence 
minus one (FMO) signal). Antibodies and intranu-
clear staining kits used for Foxp3 staining setup were 
AF700-labeled Foxp3 (clone PCH101, eBiosciences), 
PE-labeled Foxp3 (clone PCH101, eBiosciences, and 
clone 206D, R&D systems), PE-CF594-labeled Foxp3 
(clone 259D/C7, BD), AmCyan-labeled CD3 (clone 
SK7, BD), V500-labeled CD3 (clone UCHT1, BD), 
PE-CF594- or AF700-labeled CD4 (both clone RPA-T4, 
BD), PE-CY7-labeled CD25 (clone 2A3, BD), BV650-
labeled CD127 (clone HIL-7R-M21, BD), the Foxp3/
transcription factor staining buffer set (eBiosciences), 
and the BD Pharmingen Transcription Factor Buffer set 
(BD). Cell surface antibody staining was performed in 
PBS/0.5 % BSA/0.02 % sodium azide (PBA) buffer for 
30 min at 4 °C. Intranuclear Foxp3 staining was con-
ducted with the BD or eBiosciences Transcription Fac-
tor Buffer sets according to the manufacturers’ proto-
col. Analysis revealed that Foxp3 could be detected 
with all used clones when using the eBiosciences kit. 
Yet, staining intensity (and thus discrimination between 
negative and positive) was lower with the PCH101 
clones when compared with the 206D (PE) clone (Sup-
plementary figure 1a–c), which may be due to fluoro-
chrome choice. Staining pattern and positive-to-nega-
tive signal ratio [i.e., staining index (SI)] of the 259D/
C7 (PE-CF594) clone were most optimal with the BD 
TF kit (not shown) and were comparable to the stain-
ing pattern of the 206D clone using this kit, indicating 
that both antibodies could be used in our Treg panel 
(Supplementary figure 1d–f). After selection of the best 
Foxp3 antibody and intranuclear staining buffer set, all 
additional antibodies in the final panel were titrated, 
and spillover profiles were generated to ascertain that 
there was no spectral overlap of the selected antibod-
ies into the secondary detectors. Optimal antibody con-
centrations were determined based on the following 
criteria: (a) frequency and (b) highest SI (positive mean 
divided by negative mean), and spillover profiles were 
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generated as described by Murdoch et al. [25]. Antibod-
ies and kits used in the final panel were V500-labeled 
CD3 (clone UCHT1, BD), AF700-labeled CD4 (clone 
RPA-T4, BD), PE-CY7-labeled CD25 (clone 2A3, BD), 
BV650-labeled CD127 (clone HIL-7R-M21, BD), APC-
H7-labeled CD45RA (clone HI100, BD), PerCP-Cy5.5-
labeled CD8 (clone SK1, BD), PE-CF594-labeled Foxp3 
(clone 259D/C7, BD), BV421-labeled CTLA-4 (clone 
BNI3, BD), FITC-labeled Ki67 (clone 20Raj1, eBio-
sciences), APC-labeled Helios (clone 22F6, Biolegend), 
PE-labeled CD39 (clone ebioA1, eBiosciences), LIVE-
DEAD® Fixable yellow dead cell stain kit (Q-dot585, 
Life technologies), and the BD Pharmingen Transcrip-
tion Factor Buffer set. Stained cells were acquired on a 
LSR Fortessa (BD) and analyzed using DIVA software 
version 6.2. Events collected were generally >200,000 
per sample, except for one tumor-infiltrating lympho-
cyte (TIL) sample (~35,000 cells). In the latter, still 
adequate numbers (~400) of Tregs could be detected.
Treg definitions and gating strategies
Tregs were analyzed according to three commonly used 
Treg definitions in the literature: (1) the CD25posCD-
127lowFoxp3pos subset [definition 1 (def.1)] [9, 10], (2) 
the Foxp3posHeliospos Treg subset (def.2) [12, 26], and (3) 
the Foxp3hiCD45RAneg activated Treg (aTreg) and Fox-
p3intCD45RApos naïve Treg (nTreg) subsets (def.3) [8, 11]. 
Gating for CD25 and CD127 (def.1), Foxp3 and Helios 
(def.2), and Foxp3 and CD45RA (def.3) Tregs was done on 
CD3posCD4neg (i.e., CD8pos) T cells and CD3neg lympho-
cytes, respectively, and subsequently applied to CD3posCD-
4pos T cells (see also supplementary figure 2a, 3a, and 5a). 
Percentage of def.1, def.2, or def.3 Tregs is given as per-
centage within the CD4pos population.
Statistical analysis
Nonparametric (Wilcoxon signed-rank or Mann–Whitney 
test for two samples and Friedman or Kruskal–Wallis with 
Dunn’s multiple comparison test for multiple samples) and 
parametric (paired or unpaired t test for two samples or RM 
one-way ANOVA or ordinary one-way ANOVA with Tuk-
ey’s multiple comparison test for multiple samples) tests 
were performed as appropriate. All statistical tests were 
performed at the 0.05 significance level, and 95 % confi-
dence intervals were two-sided intervals. For survival anal-
ysis, the OvCa patients undergoing chemo-immunothera-
peutic therapy were grouped into two groups according to 
the median (i.e., grouped into below or above the median 
of the total group for each parameter), after which survival 
was tested using Kaplan–Meier method, and statistical 
significance of the survival distribution was analyzed by 
log-rank testing. Statistical analyses were performed using 
SPSS for Windows version 20.0 (IBM, USA) and Graph-
Pad Prism 6.02 (San Diego, USA).
Results
Generation of a rationally ranked Treg marker list
During the CIP workshop, a number of Treg analysis meth-
ods were presented. These analyses were discussed, a num-
ber of questions were formulated, and during the follow-up 
of the meeting, a rationally composed ranking list of “Treg 
markers” was generated. All markers suggested, and the 
rationale to use them is given in Table 1. To test these mark-
ers and get insight into the overlap/differences between the 
most frequently used human Treg definitions, we included 
markers 1–8, 10, and 11 for direct ex vivo analysis of 
peripheral blood samples from six HD and OvCa patients, 
and LN and tumor samples obtained from CxCa patients. 
Markers were included based on the number of participants 
opting for inclusion of the marker and/or their known asso-
ciation with Tregs. LAP/GARP (number 9) was excluded 
as this marker is only expressed >24 h following in vitro 
activation.
Analysis of Tregs according to commonly used Treg 
definitions
Tregs were analyzed according to three commonly used 
Treg definitions in the literature [8–12, 26].
Definition 1: CD25posCD127lowFoxp3pos Tregs
Figure 1a shows the expression of the different markers 
in def.1 Tregs. The gating strategy for the CD25posCD-
127lowFoxp3pos def.1 Treg subset is given for a representa-
tive HD in supplementary Fig. 2a. Cells expressing Foxp3 
comprised 78.7 % (range 70.5–85.1 %) of the CD25posCD-
127low subpopulation. Due to variability in CD127 expres-
sion (Supplementary figure 2b, c), enumerating def.1 
Tregs solely based on CD25 and CD127 is highly variable 
between HD and most likely leads to an overestimation 
of the number of Tregs (mean 17.6 %, range 7.2–30.4 %). 
Inclusion of Foxp3 resulted in less variation in the percent-
age of def.1 Tregs (mean 6.9 %, range 4.6–8.8 %) as would 
be expected among a group of HD, suggesting that simul-
taneous staining with CD25, CD127, and Foxp3 is needed 
for reliable measurement of def.1 Tregs. Further charac-
terization of the CD25posCD127lowFoxp3pos subset revealed 
that 75 % of these cells were Helios positive (Fig. 1a). 
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Moreover, the majority of CTLA-4 and Ki67 expressing 
CD4pos T cells were found in the CD25posCD127lowFoxp-
3pos population (data not shown). These observations add 
to the notion that bona fide Tregs are detected when the 
CD25posCD127lowFoxp3pos def.1 subset definition for Treg 
enumeration is used.
Definition 2: Foxp3posHeliospos Tregs
The gating strategy for the Foxp3posHeliospos def.2 Treg 
subset is given for a representative HD in supplemen-
tary figure 3a. Analysis revealed that 5.6 % of CD4pos 
T cells is Foxp3posHeliospos (range 4.1–7.1 %), and 
Fig. 1  CD25posCD127lowFoxp3pos def.1, Foxp3posHeliospos def.2, 
and Foxp3hiCD45RAneg def.3 aTregs express high levels of Treg-
associated markers, suggesting that they are bona fide Tregs. Pheno-
typic characterization of def.1, def.2, and def.3 Tregs was performed 
by flow cytometry. Gating of the three different Treg definitions was 
performed as described in supplementary figs. 2a, 3a, and 5a. Expres-
sion of the Treg-associated markers Helios, CD45RA, CTLA4, Ki67, 
and CD39 is depicted for a representative healthy donor (HD; left) 
and multiple HD (right; Helios/CD45RA/CTLA4/Ki67 for six and 
CD39 for two HD) for a CD25posCD127lowFoxp3pos def.1 Tregs, b 
Foxp3posHeliosneg and Foxp3posHeliospos def.2 Tregs, and c Foxp3h-
iCD45RAneg def.3 aTregs, Foxp3intCD45RApos def.3 nTregs, and 
Foxp3intCD45RAneg def.3 non-Tregs. Percentage Helios/CD45RA/
CTLA4/Ki67/CD39 expression is given as percentage of the des-
ignated population in the upper right quadrant in the FACS plot for 
the representative HD (left) and as mean percentage for the six HD 
(right)
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Fig. 2  Treg enumeration based solely on Foxp3 and Helios (def.2) or 
Foxp3 and CD45RA (def.3) led to an underestimation of CD25posCD-
127lowFoxp3pos def.1 Tregs through exclusion of def.1 Treg cells in 
the Foxp3posHeliosneg (def.2) or Foxp3intCD45RAneg non-Treg (def.3) 
populations. Overlap between the three most commonly used Treg 
definitions (def.1, def.2, and def.3) is given for a a representative HD 
and b, c six HDs. a Distribution of def.1 Tregs is shown in def.2 and 
def.3 populations (left), of def.2 Tregs is shown in def.1 and def.3 
populations (middle), and of def.3 Tregs is shown in def.1 and def.2 
populations (right). Percentage of Tregs analyzed via def.1, def.2, or 
a combination thereof b and via def.1, def.3, or a combination thereof 
c is depicted as percentage of CD4pos T cells. Overlap between the 
designated populations is calculated in relation to def.1 Tregs (set at 
100) and given in the bar graph for each population
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Foxp3posHeliosneg cells accounted for 2.9 % (range 1.9–
4.4 %) of CD4pos T cells. Interestingly, Foxp3 expression 
of Foxp3posHeliosneg cells was significantly lower than 
that of Foxp3posHeliospos cells (Supplementary figure 3b, 
c). Further characterization of the def.2 Treg subsets 
revealed that the majority of the Foxp3posHeliospos cells 
(mean 88 %, range 84.7–90.7 %) were found inside the 
CD25posCD127low def.1 Treg subset (Supplementary fig-
ure 4). Moreover, 64 % of Foxp3posHeliosneg cells (range 
52.0–72.9 %) could also found within that CD25posCD-
127low gate. Expression levels of CTLA4 and CD45RA 
were found similar in Foxp3posHeliosneg and Foxp3posHe-
liospos cells (Fig. 1b). Together, this indicates that although 
probably polluted with Foxp3pos activated effector T cells, 
the population of Foxp3posHeliosneg cells also contain 
considerable amounts of Tregs according to definition 1. 
Interestingly, Foxp3posHeliospos cells expressed signifi-
cantly more Ki67 compared with Foxp3posHeliosneg cells, 
suggesting that Foxp3posHeliospos cells, which also express 
higher levels of Foxp3, represent more recently activated 
Tregs (p = 0.03; Fig. 1b).
Definition 3: Foxp3hiCD45RAneg a Treg 
and Foxp3intCD45RApos n Tregs
The gating strategy for the Foxp3hiCD45RAneg and 
Foxp3intCD45RApos def.3 Treg subsets is given for a 
representative HD in supplementary figure 5a. Fox-
p3hiCD45RAneg aTreg accounted for 1.1 % (range 0.8–
1.6 %) and Foxp3intCD45RApos nTreg for 1.4 % (range 
0.6–2.5 %) of CD4pos T cells. Remarkably, the so-called 
Foxp3intCD45RAneg non-Treg subset accounted for 6.0 % 
(range 4.2–7.4 %) of CD4pos T cells, and this was sig-
nificantly more than the aTreg and nTreg frequencies 
detected (p < 0.001) (Supplementary figure 5b). Further 
characterization revealed that the majority of aTregs and 
nTregs could be found within the CD25posCD127low def.1 
and Heliospos def.2 Treg populations. Yet, the so-called 
non-Treg population also comprised considerable num-
bers of the def.1 (77.3 %) and def.2 (56.2 %) Tregs, indi-
cating that the def.3 non-Treg population still contained 
high numbers of Tregs according to the other definitions 
(Supplementary figure 6a, b, d). Moreover, the frequency 
of def.1 or def.2 Tregs within the non-Treg population 
was significantly higher than within the aTreg and nTreg 
populations (Supplementary figure 6a, c, e). As expected, 
the aTreg, but not the nTreg population, displayed an acti-
vated profile indicated by high levels of Ki67 and CTLA4 
expressions (% and mean fluorescence intensity; Fig. 1c 
and data not shown, respectively) sustaining the notion 
that this preset profile is likely to accurately detect acti-
vated Tregs.
Expression of ectonucleoside triphosphate 
diphosphohydrolase‑1 (CD39)
It has been described that human Tregs express CD39, 
an ectonucleotidase involved in adenosine triphosphate 
(ATP) breakdown and the production of immunosuppres-
sive adenosine, thereby suggesting that CD39 may be a 
functional marker on Tregs [27, 28]. To study the expres-
sion of CD39 in relation to the three commonly used Treg 
definitions, CD39 was included in our flow cytometric 
marker panel, and two HD-derived PBMC samples were 
analyzed. Although the majority of CD39 can be found in 
CD25posCD127lowFoxp3pos def.1 Tregs (~70 %), expres-
sion of CD39 is not def.1 Treg exclusive (Supplementary 
figure 7a, d). Similar results were found for Foxp3posHe-
liospos def.2 Treg and the Foxp3CD45RA def.3 Treg sub-
sets (Supplementary figures 7b, c, e, f). Interestingly and 
indeed suggestive of their functional potential, CD39 
expression is much higher in Foxp3hiCD45RAneg aTregs 
than in Foxp3intCD45RApos nTregs. Thus, CD39 expres-
sion seems to be present especially on activated Tregs, but 
its expression is not Treg exclusive. Within the activated 
Treg populations, it identifies the same population of cells, 
that is, CD45RAneg and CTLA4pos. CD39 expression there-
fore falls into the category of markers for identifying the 
activated subset of Tregs. Of note, it has been demonstrated 
that CD39, when combined with CD25, can be used to 
identify and isolate Tregs with strong suppressive activ-
ity [29, 30]. Gating on the cell surface markers CD25pos, 
CD127low, and CD39pos yielded 75–80 % Foxp3pos cells in 
our hands (Supplementary figures 7 and 8).
Based on the expression of high levels of CD25, Helios, 
CTLA-4, and CD39, the CD25posCD127lowFoxp3pos def.1, 
Foxp3posHeliospos def.2, and Foxp3hiCD45RAneg def.3 T 
cells were classified as bona fide Tregs.
Overlap between the three Treg definitions
Next, the overlap between the def.1, def.2, and def.3 Tregs 
was determined (Fig. 2a–c). As expected, there was con-
siderable overlap between the three Treg definitions. The 
overlap between the CD25posCD127lowFoxp3pos def.1 
Tregs and the Foxp3posHeliospos def.2 Tregs is approxi-
mately 73 %, and thus, Treg enumeration based solely on 
Foxp3 and Helios may lead to an underestimation in Tregs 
of ~27 % through exclusion of CD25posCD127lowFoxp-
3pos cells in the Foxp3posHeliosneg population (range 20.2–
35.3 % of CD25posCD127lowFoxp3pos Tregs; supplementary 
figure  4c). Furthermore, Treg measurements based solely 
on Foxp3 and CD45RA (def.3) led to an underestimation 
of the number of def.1 Tregs of 67.5 % through exclu-
sion of the so-called Foxp3intCD45RAneg non-Tregs (range 
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Fig. 3  Treg gating based on Foxp3 and CD45RA (def.3) is subjec-
tive in TIL as it is difficult to distinguish between Foxp3hi versus 
FoxP3low cells due to the absence of Foxp3intCD45RApos popula-
tion. Def.1, def.2, and def.3 Treg analyses were performed by flow 
cytometry. Treg analysis based on CD25 and CD127 (def.1), FoxP3 
and Helios (def.2), and FoxP3 and CD45RA (def.3) is given for 
PBMC of a representative healthy donor (HD) and an ovarian can-
cer (OvCA) patient and for a TDLN and TIL sample of representa-
tive cervical cancer (CxCa) patient in a and for multiple donors in 
b. Gates were set as described in supplementary figures 2a, 3a, and 
5a. Percentage of CD25posCD127low and CD25posCD127lowFoxp-
3pos def.1; Foxp3posHeliosneg and Foxp3posHeliospos def.2; and the 
def.3 Foxp3hiCD45RAneg aTreg, Foxp3intCD45RApos nTreg, and 
Foxp3intCD45RAneg non-Treg populations is given as percentage of 
CD3posCD4pos T cells. Example of the problem with gating based on 
Foxp3 and CD45RA in TIL is depicted by the arrow in a
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61.0–73.5 % of CD25posCD127lowFoxp3pos Tregs; supple-
mentary figure 6c).
Treg enumeration in PBMC, TDLN, and TIL of cancer 
patients
It has been described that the expression of CD25 and/
or CD127 can be altered in (chronic) inflammatory/auto-
immune diseases such as systemic lupus erythematosus 
(SLE) and type 1 diabetes, thereby influencing reliable 
Treg enumeration [12, 26, 31]. In addition, changes in 
CD25 and CD127 expressions have also been observed 
in cancer patients undergoing immunotherapeutic inter-
ventions such as vaccination or ipilimumab treatment 
[32–35]. To study the possibility of analyzing Tregs by 
the different definitions under such conditions, we ana-
lyzed peripheral blood samples from patients with recur-
rent OvCa and TDLN and tumor samples from CxCa 
patients.
As shown in Fig. 3 for representative examples, 
the gating and enumeration of Tregs based on CD25, 
CD127, Foxp3 (def.1), and Foxp3 and Helios (def.2) 
is feasible in OvCa-derived peripheral blood, as well 
as in TDLN and tumor samples from CxCa patients 
using the same gating strategy applied for HD-derived 
PBMC. Treg enumeration based on def.3 was feasible 
in peripheral blood and TDLN samples of patients but 
was not reliable in tumor samples due to the absence of 
the Foxp3intCD45RApos nTreg population which is used 
for discrimination between Foxp3int and Foxp3hi cells in 
the gating strategy (see also Supplementary figure 5 for 
Foxp3 and CD45RA gating strategy). Figure 3b shows a 
summary of the detected Treg frequencies in all analyzed 
samples. Importantly, the overlap between the three Treg 
subsets was comparable between HD-derived and OvCa 
patient-derived peripheral blood, CxCa-derived TDLN 
and tumor samples (Supplementary figure 9), indicat-
ing that CD25, CD127, and Foxp3 can also be used in 
cancer condition tissues. Of note, the additional value of 
CD127 and CD25 in the def.1 Treg marker set becomes 
particularly clear upon exclusion of these markers when 
assessing Treg frequencies in these samples. Exclusion 
of CD127 and/or CD25 from the Treg panel resulted in 
increase in the number of detected def.1 Tregs (supple-
mentary figure 10). Although exclusion of CD127 only 
led to a substantial increase in the frequency of def.1 
Tregs (mean 21.5 %, range 14.7–29.3 %) in the PBMC 
of OvCa patients, exclusion of CD25 or CD25 and 
CD127 led to substantial increases in the frequency of 
these def.1 Tregs in PBMC of HD and OvCa patients as 
well as in TDLN or tumor samples from CxCa patients 
(17.9, 21.9, 24.0, and 30.8 % for CD25 exclusion and 
37.6, 58.8, 40.4, and 43.3 % for CD25 and CD127 
exclusions, see supplementary figure 10a). This resulted 
from a less pure Treg detection as reflected by lower 
percentage of def.1 Tregs expressing markers such as 
CTLA-4 and reduced frequencies of Heliospos def.2 and 
Foxp3hiCD45RAneg def.3 aTreg cells among the def.1 
Tregs (supplementary figure 10b), indicating that CD25 
and CD127 are required for reliable assessment of def.1 
Tregs.
The association between Tregs and survival
Treg accumulation in the tumor or peripheral blood is 
associated with tumor progression and poor prognosis 
[3–6]. To study the relation between the different Treg 
subsets and survival, we determined the frequencies of 
the def.1, def.2, and def.3 Tregs in the PBMC of recurrent 
OvCa patients undergoing chemo-immunotherapeutic 
treatment (EM Dijkgraaf et al. submitted for publication) 
and correlated these levels to the overall survival (OS). 
Pretreatment levels of none of the def.1 Tregs, def.2 
Tregs, and def.3 aTreg correlated with survival (Fig. 4a). 
However, when the pretreatment frequencies of Fox-
p3hiCD45RAneg or Ki67pos cells within def.1 Tregs (i.e., 
activated def.1 Tregs) were determined, a trend toward 
reduced OS was observed for patients with high frequen-
cies of Foxp3hiCD45RAneg def.1 Tregs (p = 0.0643) and 
a significant reduced OS for patients with high frequen-
cies of Ki67pos def.1 Tregs (p = 0.0133; Fig. 4b). The lat-
ter suggests that in particular, measurements of a more 
activated Treg pool may have prognostic or predictive 
value.
Fig. 4  High pretreatment frequencies of Foxp3hiCD45RAneg and 
Ki67pos def.1 Tregs (i.e., activated def.1 Tregs) are associated with 
reduced overall survival in OvCa patients undergoing chemo-
immunotherapeutic therapy. The use of Ki67 and CD45RA provides 
additional information on the activation status of def.1 Tregs. Treg 
analysis was performed based on CD25, CD127, and Foxp3 (def.1), 
Foxp3 and Helios (def.2), and Foxp3 and CD45RA (def.3) in PBMC 
of 21 chemo-immunotherapy-treated ovarian cancer (OvCA) patients 
(EM Dijkgraaf et al., submitted for publication). Pretreatment val-
ues of def.1, def.2, and def.3 Tregs were determined, and overall 
survival (OS) of these patients following chemo-immunotherapy 
was plotted in Kaplan–Meier curves for pretreatment values of def.1 
(left), def.2 (middle), and def.3 (right) Tregs in a. Activation status 
of def.1 Tregs was determined by measuring the frequency of Fox-
p3hiCD45RAneg and Ki67pos cells within the def.1 Tregs. Gating 
and Kaplan–Meier curves are depicted in b for pretreatment values 
of Foxp3hiCD45RAneg def.1 Tregs and c for pretreatment values of 
Ki67pos def.1 Tregs. Gates for Foxp3hiCD45RAneg and Ki67pos were 
set as shown in the FACS plots. Patients were grouped into two 
groups based on the median of the total population, i.e., into a group 
of patients with frequencies that were below the median (dotted line) 
or with frequencies above the median (solid line) for the indicated 
parameter, after which survival analysis was performed. Number of 
patients and corresponding OS for each group is given. Statistical 
analysis was performed by log-rank testing, and differences were 
considered significant when p < 0.05
▸
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Conclusion and discussion
The unambiguous enumeration of Tregs by flow cytometry 
is hampered by (a) the inability to directly measure their 
function and (b) the absence of an exclusive, highly spe-
cific marker. Reaching consensus on an essential marker 
set for Treg enumeration with the currently available mark-
ers involves a number of considerations. First, the essential 
marker set should be able to identify a population of cells 
that in addition to the essential Treg-defining markers also 
express other Treg-associated markers but do not produce 
IFNγ and IL-2 [12, 13, 26]. Secondly, as there are cur-
rently three Treg definitions used in the field [8–12, 26], 
the cell population identified should be highly specific and 
include at least the same population of Tregs by all three 
definitions. Third, the proposed marker set should allow for 
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robust, undisputable, and context (tissue)-independent gat-
ing since differences in gating strategies have been found 
to be the biggest source for interassay variation in flow 
cytometry-based assays [16, 17]. Fourth, if possible, one 
should be able to assess their functionality.
Based on the data presented here and taking into account 
the above-mentioned considerations, we consider the use of 
the CD3, CD4, CD25, CD127, and Foxp3 markers as the 
minimally required markers to define human Tregs. We 
showed that this combination of markers allows for robust 
and undisputable gating of Tregs in the context of HD- and 
cancer patient-derived peripheral blood as well as TDLN 
and tumor samples (Supplementary figure 2 and Fig. 3). 
Although the latter also holds true for Foxp3posHelios-
pos def.2 Tregs (Supplementary figure 3 and Fig. 3), Treg 
measurement based solely on Foxp3 and Helios resulted 
in a ~25 % underestimation of the number of def.1 Tregs 
through exclusion of CD25posCD127low cells within the 
Foxp3posHeliosneg population in all tested tissues/compart-
ments (supplementary figure 4 and 9). These observations 
were in line with findings from others, reporting that Helios 
expression was restricted to a subpopulation (approxi-
mately 70 %) of human Foxp3pos T(reg) cells [12, 13, 26]. 
Treg enumeration based on Foxp3 and CD45RA (def.3) 
yielded distinctive aTreg and nTreg populations in HD- 
and cancer patient-derived peripheral blood and TDLN, 
with high CD25, CTLA-4, and Ki67 expression levels in 
the aTreg and lower expression levels of these markers in 
the nTreg populations (Supplementary figure 6 and figure 1 
and 3). Yet, in line with findings from others [12], the larg-
est population of CD25posCD127lowFoxp3pos (def.1; sup-
plementary figure 6c) or Foxp3posHeliospos (def.2; supple-
mentary figure 6e) populations was found in the so-called 
non-Treg population of Foxp3intCD45RAneg cells. While 
the population of Tregs based on definitions 1 or 2 may 
contain small fractions on non-Tregs, the measurement of 
Tregs based solely on Foxp3 and CD45RA (def.3) will lead 
to a ~60–70 % underestimation of Tregs. Importantly, def.3 
Treg gating could not be done in a robust and undisputable 
fashion in tumor samples. Although not unexpected and 
observed before [8], the absence of the Foxp3intCD45RApos 
T cell population in tumor samples precluded robust def.3 
aTreg and nTreg gatings in this context. Notably, the appar-
ent absence of naïve T cells at tumor effector sites and the 
preferential recruitment of activated Tregs or accumula-
tion of locally activated Tregs does confirm the validity of 
the defined respective activated and naïve Treg definitions 
within definition 3 [8, 11]. Of note, this observation clearly 
emphasizes the need for validating/assessing the suitability 
of the flow cytometry panels in the intended context/tissue.
As shown, we used CD3posCD4neg (i.e., CD8pos) and 
CD3neg cells to define the limits of the positive (CD25, 
CD127, Helios, and CD45RA) gates as this has been 
described to form a more reliable gating strategy than using 
isotype control antibodies or FMO controls [23]. Omission 
of CD3 and CD8 antibodies from the essential marker set 
does affect our gating strategy resulting in less reliable/
more disputable CD25, CD127, Helios, and CD45RA gat-
ing, and thus affecting the reliability of our results (data not 
shown). Furthermore, this gating strategy results in objec-
tive CD25pos gating rather than subjective CD25high gating, 
the latter being very important for harmonized and compar-
ative Treg analysis.
There are a number of Treg-associated markers which 
we consider to be of interest, yet optional to the required 
minimal panel. Based on our data, we highly recommend 
Table 2  Proposed marker set
a Proposed order based on the outcome of the CIP workshop on the detection and functional testing of (antigen specific) regulatory T cells, sub-
sequent discussions with leading experts in the field and data presented here
Ordera Marker Expression Location Advice Comment
1 CD3 Directly ex vivo Cell surface Essential
2 CD4 Directly ex vivo Cell surface Essential
3 CD25 Directly ex vivo Cell surface Essential
4 Foxp3 Directly ex vivo Intranuclear Essential
5 CD127 Directly ex vivo; low/absent Cell surface Essential
6 Ki67 Directly ex vivo Intranuclear Highly recommended In recently activated/proliferating Tregs
7 CD45RA Directly ex vivo Cell surface Highly recommended Discriminates between naïve and TCR-
triggered Tregs
8 CTLA4 Directly ex vivo Intracellular Optional On (previously) activated Tregs
9 Helios Directly ex vivo Intranuclear Optional Superior to CD25/CD127 in autoimmune 
conditions (such as SLE)
10 CD39 Directly ex vivo Cell surface Optional Present on suppressive Tregs
11 LAP/GARP Upon activation (>24 h) on PBMC/
directly ex vivo on TIL
Intracellular Optional On activated Tregs
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extending the minimally required antibody panel to include 
Ki67 and CD45RA as they provide additional information 
on the Treg activation status (Table 2). Indeed, the addi-
tion of CD45RA and Ki67 to the marker panel proved very 
informative in that no def.1, def.2, or def.3 Tregs were 
associated with worse survival of ovarian cancer patients 
but only the pretreatment frequencies of activated Foxp-
3posCD45RAneg and Ki67pos def.1 Tregs (Fig. 4). The meas-
urement of activated Ki67pos Tregs has also been advocated 
by others [36, 37]. In one study, renal cell cancer patients 
undergoing multipeptide vaccination and cyclophospha-
mide treatment showed a significant reduction in the num-
ber of circulation Ki67pos Tregs and a trend toward pro-
longed OS following therapy [37]. Of note, as Ki67pos def.1 
Treg detection was also feasible in TDLN and tumor sam-
ples (not shown), this strategy may also be useful to iden-
tify activated Tregs within def.1 Tregs in tumor samples, 
thereby circumventing the need for the subjective gating on 
Foxp3hi versus Foxp3int cells. While the activation markers 
CD39 and CTLA-4 [27, 28, 38, 39] have been described as 
functional markers to identify activated Tregs, they do not 
provide additional information to a panel over CD45RA 
and Ki67 and the minimally required antibody set. Helios 
may be of interest for identifying Tregs in autoimmunity 
such as SLE since these patients’ conventional T cells dis-
play high levels of CD25 resulting in overlap with Tregs 
[12]. In a recent trial where patients displayed a strong anti-
gen-specific CD4pos T cell response to vaccination, we did 
not observe such problems for identifying Tregs using the 
currently proposed markers (EM Dijkgraaf et al. submitted 
for publication). Based on our data, omission of CD25 as 
a marker is not recommended as this resulted in the iden-
tification of less pure Treg populations (Supplementary 
figure 10).
In addition, there remains a number of markers, not 
tested in this study, which may offer benefits to identify 
specific subsets of Tregs. CD147 is a cell surface marker 
that is accessible directly ex vivo and can also be used to 
identify an activated and highly suppressive Treg subset 
[36, 40, 41]. Furthermore, LAP (membrane-bound active 
form of TGF-β) and GARP (membrane-anchoring mol-
ecule involved in latent TGF-β binding) may be particu-
larly interesting in defining TGF-β-associated and acti-
vated Tregs in tumor samples [39, 42–45]. Moreover, the 
chemokine receptors CCR6, CXCR3, CCR4, and CCR10 
were found to be useful for the identification of phenotypi-
cal and functional distinct subsets of human Foxp3+ Tregs 
[46].
In summary, consensus was reached concerning the 
use of an essential marker set comprising antibodies to 
CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA 
and a corresponding robust gating strategy for the analy-
sis of Tregs in human samples. This set will be used in 
proficiency panels to harmonize the phenotypic analysis of 
Tregs within laboratories participating in the CIP.
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